These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 24887236)

  • 1. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
    Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
    Fang H; Jin J; Huang D; Yang F; Guan X
    Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
    Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
    J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
    Huang C; Park CC; Hilsenbeck SG; Ward R; Rimawi MF; Wang YC; Shou J; Bissell MJ; Osborne CK; Schiff R
    Breast Cancer Res; 2011 Aug; 13(4):R84. PubMed ID: 21884573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
    Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
    MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-221 confers lapatinib resistance by negatively regulating p27
    Huynh TK; Huang CH; Chen JY; Yao JH; Yang YS; Wei YL; Chen HF; Chen CH; Tu CY; Hsu YM; Liu LC; Huang WC
    Cancer Sci; 2021 Oct; 112(10):4234-4245. PubMed ID: 34382727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
    Zhang S; Huang WC; Zhang L; Zhang C; Lowery FJ; Ding Z; Guo H; Wang H; Huang S; Sahin AA; Aldape KD; Steeg PS; Yu D
    Cancer Res; 2013 Sep; 73(18):5764-74. PubMed ID: 23913825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.
    De Luca A; D'Alessio A; Gallo M; Maiello MR; Bode AM; Normanno N
    Cell Cycle; 2014; 13(1):148-56. PubMed ID: 24200972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
    PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
    Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
    BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
    Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
    Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
    Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.
    Lin CH; Pelissier FA; Zhang H; Lakins J; Weaver VM; Park C; LaBarge MA
    Mol Biol Cell; 2015 Nov; 26(22):3946-53. PubMed ID: 26337386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
    Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
    Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.